Inventiva S.A. (IVA)

Inventiva S.A. is a clinical-stage biopharmaceutical company dedicated to developing oral small molecule therapies. Their lead product, Lanifibranor, targets NASH and has completed Phase IIb clinical trials, marking a significant step towards addressing unmet medical needs.

45/100 AI Score MCap 239M Vol 281K

Company Overview

CEOAndrew Obenshain
Employees114
HeadquartersDaix, FR
IPO Year2020

Inventiva S.A. pioneers oral small molecule therapies, highlighted by Lanifibranor's progress in treating NASH, positioning the company at the forefront of innovative solutions for metabolic diseases and fibrotic conditions, offering a compelling investment in cutting-edge biotechnology.

Investment Thesis

Inventiva S.A. presents a compelling investment opportunity due to its focused pipeline targeting significant unmet medical needs. The lead candidate, Lanifibranor, holds substantial promise in the NASH market, a space with limited approved therapies. Positive Phase IIb results provide a strong foundation for further development. The company's strategic collaborations with AbbVie and Boehringer Ingelheim validate its research and development capabilities. With a market capitalization of $0.31 billion, Inventiva offers potential for significant upside if Lanifibranor progresses successfully through late-stage clinical trials and gains regulatory approval. Key value drivers include successful Phase III trial outcomes, strategic partnerships, and potential acquisition interest. The gross margin of 86.4% indicates a strong potential for profitability upon commercialization.

Key Highlights

  • Lanifibranor, the lead product candidate, has completed Phase IIb clinical trial for NASH, demonstrating potential in a high-need market.
  • Strategic collaborations with AbbVie and Boehringer Ingelheim validate Inventiva's research and development capabilities and provide potential revenue streams.
  • Gross margin of 86.4% indicates strong potential for profitability upon successful commercialization of its therapies.
  • Market capitalization of $0.31 billion presents an opportunity for significant growth if clinical trials are successful.
  • The company is developing Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease, addressing a rare genetic disorder.

Competitors

Strengths

  • Promising lead product candidate, Lanifibranor, for NASH.
  • Strategic collaborations with AbbVie and Boehringer Ingelheim.
  • Strong gross margin potential.
  • Proprietary drug development platform.

Weaknesses

  • Clinical-stage company with no currently approved products.
  • Negative profit margin.
  • Reliance on successful clinical trial outcomes.
  • Limited financial resources compared to larger pharmaceutical companies.

Catalysts

  • Upcoming: Phase III clinical trial results for Lanifibranor in NASH.
  • Ongoing: Potential for new strategic partnerships and licensing agreements.
  • Ongoing: Advancement of Odiparcil through clinical development.
  • Ongoing: Expansion of Lanifibranor into additional fibrotic disease indications.

Risks

  • Potential: Clinical trial failures for Lanifibranor or Odiparcil.
  • Potential: Regulatory delays or rejection of marketing applications.
  • Ongoing: Competition from other companies developing NASH therapies.
  • Potential: Patent challenges and intellectual property disputes.
  • Ongoing: Dependence on external funding to support research and development.

Growth Opportunities

  • Lanifibranor's Phase III Success: The successful completion of Phase III clinical trials for Lanifibranor in NASH represents a significant growth opportunity. The NASH market is projected to reach billions of dollars in the coming years, and a successful therapy could capture a substantial market share. Positive trial results would not only drive revenue but also increase the company's valuation and attract further investment. Timeline: Anticipated Phase III results within the next 2-3 years.
  • Expansion into Additional Indications: Inventiva has the opportunity to expand the application of Lanifibranor into other fibrotic diseases beyond NASH. Fibrosis is a common pathological process in various organs, and Lanifibranor's pan-PPAR agonist activity could potentially address these conditions. This expansion would significantly broaden the market opportunity and diversify the company's revenue streams. The market size for fibrotic diseases is substantial and growing. Timeline: Exploration of new indications within the next 3-5 years.
  • Advancement of Odiparcil for MPS VI: The successful development and commercialization of Odiparcil for MPS VI represents another growth avenue. While MPS VI is a rare disease, the high cost of orphan drugs can result in significant revenue. Positive clinical trial outcomes and regulatory approval would establish Inventiva as a leader in the treatment of rare genetic disorders. Timeline: Potential market launch within the next 3-4 years.
  • Strategic Partnerships and Licensing Agreements: Inventiva can leverage its research and development capabilities to establish additional strategic partnerships and licensing agreements with larger pharmaceutical companies. These collaborations can provide upfront payments, milestone payments, and royalties, generating significant revenue and validating the company's technology. The market for licensing agreements in the biotechnology sector is robust. Timeline: Ongoing pursuit of new partnerships.
  • Pipeline Expansion through Internal Research and Development: Inventiva can continue to invest in its internal research and development programs to expand its pipeline of novel therapies. This includes exploring new targets and modalities for the treatment of metabolic diseases, fibrotic conditions, and other areas of unmet medical need. A diversified pipeline reduces risk and increases the potential for long-term growth. Timeline: Continuous investment in R&D.

Opportunities

  • Large and growing NASH market.
  • Expansion into additional indications for Lanifibranor.
  • Potential for further strategic partnerships.
  • Advancement of Odiparcil for MPS VI.

Threats

  • Clinical trial failures.
  • Regulatory hurdles and delays.
  • Competition from other companies developing NASH therapies.
  • Patent challenges and intellectual property disputes.

Competitive Advantages

  • Proprietary drug candidates with patent protection.
  • Clinical trial data demonstrating efficacy and safety.
  • Strategic collaborations with leading pharmaceutical companies.
  • Expertise in developing oral small molecule therapies.
  • Focus on addressing unmet medical needs in specific disease areas.

About

Founded in 2011 and based in Daix, France, Inventiva S.A. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative oral small molecule therapies. The company's primary focus is on addressing significant unmet medical needs in the areas of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases with significant fibrotic components. Inventiva's lead product candidate, Lanifibranor, is a pan-PPAR agonist that has completed a Phase IIb clinical trial for the treatment of NASH, a prevalent and severe liver disease. Beyond NASH, Inventiva is also developing Odiparcil, currently in Phase IIa clinical trials, for the treatment of MPS VI, a rare genetic disorder. Inventiva's strategic approach involves targeting key biological pathways with the potential to modify disease progression. The company also has a pipeline of earlier-stage programs in oncology and other diseases, demonstrating a commitment to expanding its therapeutic reach. Furthermore, Inventiva has established strategic collaborations with industry leaders such as AbbVie for autoimmune diseases and Boehringer Ingelheim for idiopathic pulmonary fibrosis, underscoring the value of its research and development capabilities. With a team of 114 employees, Inventiva is dedicated to advancing its pipeline and delivering innovative therapies to patients in need.

What They Do

  • Develop oral small molecule therapies.
  • Focus on treating non-alcoholic steatohepatitis (NASH).
  • Develop treatments for mucopolysaccharidoses (MPS).
  • Research therapies for other diseases with fibrotic components.
  • Advance Lanifibranor, a pan-PPAR agonist, for NASH treatment.
  • Develop Odiparcil for the treatment of MPS VI.
  • Engage in strategic collaborations with pharmaceutical companies.
  • Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.

Business Model

  • Develop and patent novel therapeutic compounds.
  • Conduct preclinical and clinical trials to demonstrate safety and efficacy.
  • Seek regulatory approval from health authorities.
  • Commercialize approved therapies directly or through partnerships.
  • Generate revenue through product sales, licensing agreements, and milestone payments.

Industry Context

Inventiva operates within the biotechnology industry, which is characterized by high innovation, intense competition, and significant regulatory hurdles. The NASH market, in particular, is a rapidly growing area with a high unmet need, driven by the increasing prevalence of obesity and diabetes. The competitive landscape includes companies like AVTX (Aravive, Inc.), CRBU (Caribou Biosciences, Inc.), ENTA (Entasis Therapeutics Holdings Inc.), EPRX (Epiphany Biosciences), and GNFT (Genfit SA), all vying to develop effective therapies for liver diseases and related conditions. The biotechnology sector is projected to continue its growth trajectory, fueled by advancements in genomics, personalized medicine, and novel drug delivery systems.

Key Customers

  • Patients suffering from NASH.
  • Patients with MPS VI and other rare genetic disorders.
  • Pharmaceutical companies seeking to license or acquire novel therapies.
  • Healthcare providers who prescribe and administer Inventiva's therapies.
  • Payers, including insurance companies and government healthcare programs.
AI Confidence: 72% Updated: 2/9/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 2025 $46,000 $0 $0.00
Q4 2023 $16M $0 $0.00
Q2 2023 $2M $0 $0.00

Source: Company filings

Chart & Info

Price Chart

Inventiva S.A. (IVA) stock price: $4.60 (-0.16, -3.36%)

Why Bull

  • •Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
  • •Community sentiment has shifted positively, with increased discussions around Inventiva's innovative treatments and their impact on rare diseases.
  • •The company has made strides in clinical trials, which has garnered attention and optimism from investors looking for breakthrough therapies.
  • •Positive media coverage around their recent partnerships has created a buzz, enhancing the company's reputation within the biotech space.

Why Bear

  • •Concerns about the company's burn rate have surfaced, leading some investors to question its sustainability in the current market environment.
  • •Recent social sentiment has shown mixed feelings, with some community members expressing doubts about the timeline for product commercialization.
  • •Increased competition in the biotech sector raises fears about Inventiva's ability to maintain its market position against larger, more established firms.
  • •Regulatory hurdles remain a significant concern, as delays in approvals can impact investor confidence and project timelines.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
280,283

Rationale

AI-generated technical analysis for IVA including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Inventiva S.A. (IVA) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for IVA.

Make a Prediction

Set your price target for Inventiva S.A. (IVA), choose a timeframe, and track your prediction accuracy.

Current price: $4.60

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IVA.

Price Targets

Wall Street price target analysis for IVA.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

44.5/100

Score Factors

  • Revenue Growth 2/100

    Revenue declined -47.4% YoY, signaling shrinking demand or market headwinds.

  • Gross Margin 10/100

    Gross margin of 95.2% shows excellent pricing power and a strong competitive moat.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates IVA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Inventiva S.A. do?

Inventiva S.A. is a clinical-stage biopharmaceutical company that specializes in the development of oral small molecule therapies. Their primary focus is on addressing unmet medical needs in areas such as non-alcoholic steatohepatitis (NASH) and mucopolysaccharidoses (MPS). The company's lead product candidate, Lanifibranor, is being developed for the treatment of NASH, a liver disease with limited treatment options. Inventiva aims to develop and commercialize innovative therapies that can improve the lives of patients suffering from these debilitating conditions, either directly or through strategic partnerships.

Is IVA stock a good buy?

IVA stock represents a high-risk, high-reward investment opportunity. The company's future is heavily dependent on the successful development and commercialization of Lanifibranor for NASH. While the Phase IIb results were promising, Phase III trials are critical. The current market capitalization of $0.31 billion suggests significant upside potential if Lanifibranor succeeds. However, investors should be aware of the risks associated with clinical-stage biopharmaceutical companies, including the possibility of clinical trial failures and regulatory setbacks. A balanced portfolio approach is recommended.

What are the main risks for IVA?

The main risks for Inventiva S.A. revolve around the clinical development and regulatory approval of its drug candidates. Clinical trial failures are a significant risk, as negative results could halt the development of Lanifibranor or Odiparcil. Regulatory hurdles and delays could also impact the timeline for commercialization. Furthermore, the company faces competition from other companies developing NASH therapies. Intellectual property disputes and patent challenges could also pose a threat. Finally, Inventiva is dependent on external funding to support its research and development activities, which could be a risk if funding becomes scarce.

Is IVA a good stock to buy?

Whether IVA is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the IVA MoonshotScore?

The MoonshotScore for IVA is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is IVA data updated?

IVA stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to IVA is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for IVA?

Growth catalysts for Inventiva S.A. (IVA) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Inventiva S.A.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are IVA's main competitors?

Inventiva S.A. (IVA) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether IVA has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about IVA?

Wall Street analyst coverage for IVA includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is IVA's market cap?

Market capitalization (market cap) for IVA is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows IVA's current market cap alongside enterprise value and other valuation metrics.

How has IVA stock performed recently?

IVA's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing IVA's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in IVA?

Key risk categories for IVA include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures IVA's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling IVA?

Insider trading activity for IVA tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is IVA a good stock for beginners?

Inventiva S.A. (IVA) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is IVA for first-time investors?

Every stock carries risk, including Inventiva S.A. (IVA). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like IVA.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Information is based on publicly available sources and may be subject to change.
  • Investment decisions should be based on individual risk tolerance and due diligence.
Data Sources
profilefundamentalsexistingCopy